Equities research analysts expect Endologix, Inc. (NASDAQ:ELGX) to post earnings of ($1.57) per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Endologix’s earnings, with the lowest EPS estimate coming in at ($2.40) and the highest estimate coming in at ($1.10). Endologix posted earnings of ($1.60) per share in the same quarter last year, which would indicate a positive year over year growth rate of 1.9%. The business is expected to issue its next earnings results on Wednesday, May 1st.
On average, analysts expect that Endologix will report full year earnings of ($6.21) per share for the current fiscal year, with EPS estimates ranging from ($8.70) to ($3.90). For the next financial year, analysts forecast that the business will post earnings of ($5.51) per share, with EPS estimates ranging from ($7.60) to ($3.60). Zacks’ EPS averages are an average based on a survey of research analysts that follow Endologix.
Several brokerages recently commented on ELGX. Zacks Investment Research cut Endologix from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. BTIG Research reaffirmed a “buy” rating on shares of Endologix in a research report on Tuesday, February 26th. Finally, ValuEngine raised Endologix from a “hold” rating to a “buy” rating in a research report on Wednesday, March 6th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $29.17.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Rhumbline Advisers raised its holdings in shares of Endologix by 40.2% in the fourth quarter. Rhumbline Advisers now owns 106,979 shares of the medical instruments supplier’s stock valued at $77,000 after buying an additional 30,701 shares during the last quarter. Jane Street Group LLC increased its position in Endologix by 54.6% in the fourth quarter. Jane Street Group LLC now owns 93,572 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 33,044 shares during the period. Citigroup Inc. increased its position in Endologix by 279.2% in the fourth quarter. Citigroup Inc. now owns 51,448 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 37,882 shares during the period. BlackRock Inc. increased its position in Endologix by 1.0% in the third quarter. BlackRock Inc. now owns 5,699,104 shares of the medical instruments supplier’s stock worth $10,885,000 after purchasing an additional 54,666 shares during the period. Finally, Macquarie Group Ltd. acquired a new stake in Endologix in the fourth quarter worth about $46,000.
Endologix Company Profile
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
See Also: Retained Earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.